EU Clinical Trial 2018-000399-13

A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced squamous NSCLC (sqNSCLC) harbouring FGFR genetic alterations after relapse of standard therapy  Mar 8, 2019

Main objective of the trial: To evaluate the efficacy of erdafitinib in sqNSCLC with FGFR genetic alteration


Erdafitinib Erdafitinib 3mg Tablets Erdafitinib 4mg Tablets Erdafitinib 5mg Tablets JNJ-427556493 Non-small cell lung cancer

JSON preview

Similar records


Source:  EMA Last updated:  May 30, 2019

From, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.